STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
NCT01551693
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class
Stopped
due to weak accrual
Conditions
Melanoma
Interventions
DRUG:
STA-9090
Sponsor
Dana-Farber Cancer Institute
Collaborators
[object Object]